Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial to Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj. (Hyaluronidase, Recombinant) in Healthy Adults

NCT05922813 is registered in ClinicalTrials.gov with BMI Korea as lead sponsor.

NCT NCT05922813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05922813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj. (Hyaluronidase, Recombinant) in Healthy Adults
Lead sponsor
BMI Korea
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2022
Completion date
April 12, 2023
Enrollment
257 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

health, subjective